Arthur F Ryan sold $99k of REGN
director at REGENERON PHARMACEUTICALS, INC.. 100 shares at an average of $994.50, traded Jun 3, 2024, filed Jun 5, 2024.
Score components
- +15RoleDirector
- +10Trade size$99k at market
- 0Share of holdings soldSold 0.6% of holdings
- +15Cluster6 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +2.8%, 3m +17.2%, 6m -25.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001968202-24-000099, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 3, 2024 | SOpen-market sale Common Stock10b5-1 | -2 | $979.40 | $1,959 | 18,080 | Jun 5, 2024 |
| Jun 3, 2024 | SOpen-market sale Common Stock10b5-1 | -3 | $980.16 | $2,940 | 18,077 | Jun 5, 2024 |
| Jun 3, 2024 | SOpen-market sale Common Stock10b5-1 | -3 | $981.95 | $2,946 | 18,074 | Jun 5, 2024 |
| Jun 3, 2024 | SOpen-market sale Common Stock10b5-1 | -1 | $982.99 | $983 | 18,073 | Jun 5, 2024 |
| Jun 3, 2024 | SOpen-market sale Common Stock10b5-1 | -2 | $984.52 | $1,969 | 18,071 | Jun 5, 2024 |
| Jun 3, 2024 | SOpen-market sale Common Stock10b5-1 | -2 | $988.66 | $1,977 | 18,069 | Jun 5, 2024 |
| Jun 3, 2024 | SOpen-market sale Common Stock10b5-1 | -4 | $990.74 | $3,963 | 18,065 | Jun 5, 2024 |
| Jun 3, 2024 | SOpen-market sale Common Stock10b5-1 | -7 | $992.19 | $6,945 | 18,058 | Jun 5, 2024 |
| Jun 3, 2024 | SOpen-market sale Common Stock10b5-1 | -12 | $993.20 | $12k | 18,046 | Jun 5, 2024 |
| Jun 3, 2024 | SOpen-market sale Common Stock10b5-1 | -5 | $994.25 | $4,971 | 18,041 | Jun 5, 2024 |
| Jun 3, 2024 | SOpen-market sale Common Stock10b5-1 | -6 | $995.76 | $5,975 | 18,035 | Jun 5, 2024 |
| Jun 3, 2024 | SOpen-market sale Common Stock10b5-1 | -12 | $996.83 | $12k | 18,023 | Jun 5, 2024 |
| Jun 3, 2024 | SOpen-market sale Common Stock10b5-1 | -15 | $997.76 | $15k | 18,008 | Jun 5, 2024 |
| Jun 3, 2024 | SOpen-market sale Common Stock10b5-1 | -14 | $998.44 | $14k | 17,994 | Jun 5, 2024 |
| Jun 3, 2024 | SOpen-market sale Common Stock10b5-1 | -7 | $999.43 | $6,996 | 17,987 | Jun 5, 2024 |
| Jun 3, 2024 | SOpen-market sale Common Stock10b5-1 | -5 | $1,000.04 | $5,000 | 17,982 | Jun 5, 2024 |
Related signals
Other insiders at REGENERON PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | REGENERON PHARMACEUTICALS, INC. | Kathryn Guarini director | $340k 400 shares | -40% | |
| 33Weak | REGENERON PHARMACEUTICALS, INC. | Marion McCourt EVP Commercial | $2.0M 2,346 shares | -16% | |
| 12Weak | REGENERON PHARMACEUTICALS, INC. | Kathryn Guarini director | $320k 400 shares | -40% | |
| 18Weak | REGENERON PHARMACEUTICALS, INC. | Huda Y Zoghbi director | $640k 800 shares | -32% | |
| 6Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $130k 200 shares | -1% | |
| 3Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $71k 100 shares | -1% | |
| 4Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $78k 100 shares | -1% | |
| 12Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $79k 100 shares | -1% | |
| 30Weak | REGENERON PHARMACEUTICALS, INC. | Huda Y Zoghbi director | $1.3M 1,638 shares | -49% | |
| 30Weak | REGENERON PHARMACEUTICALS, INC. | Jason Pitofsky SVP Controller | $1.6M 2,036 shares | -32% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.